With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Alyftrek is approved to treat people ages 6 and older who have the genetic condition called cystic fibrosis. Cystic fibrosis happens because of a change in a gene on chromosome 7.

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...

When assessing safety, a comparable proportion of those receiving Alyftrek and those receiving Trikafta experienced an adverse event (96% in each of the pooled groups), with mild or moderate as ...

Alyftrek once daily (vanzacaftor 20 mg/tezacaftor 100 mg/deutivacaftor 250 mg) or; ELX/TEZ/IVA (same dosage as run-in period). The primary endpoint was absolute change in percent predicted forced ...

Alyftrek, a Key Product in VRTX's CF Portfolio. Vertex holds a dominant position in the CF market. Its CF sales continue to grow, driven by the demand growth of the blockbuster drug, Trikafta ...

ALYFTREK is approved in the EU for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane ...